智通财经APP讯，中国健康科技集团(01069)发布公告，于2025年12月9日，董事会决议建议采纳股份计 划(须待股东批准后，方可作实)，以令本公司进一步将其董事及主要雇员的长远利益与本公司利益保持 一致，并激励彼等持续推动本公司的增长及发展。 ...

董事会拟于股东特别大会上向股东建议采纳股份奖励计划。建议采纳股份奖励计划将涉及本公司授出奖 励股份。因此，采纳股份奖励计划将须待(其中包括)股东于股东大会上批准后方可作实，并可为本公司 提供另一渠道，以具竞争力及吸引力的薪酬待遇激励选定参与者为本集团的增长及发展作出贡献，并使 本集团能够吸引及挽留最优秀的人才，以发展本集团的业务。董事(包括独立非执行董事)认为，采纳股 份奖励计划符合市场惯例，激励合资格参与者致力提升企业价值及实现长期目标，以谋求本集团整体利 益。 智通财经APP讯，粤港湾控股(01396)发布公告，于2025年12月8日，董事会已决议终止现有股份期权计 划。本公司于2019年5月30日采纳现有股份期权计划，旨在通过授出股份期权鼓励及/或奖励对本集团作 出贡献的本集团成员公司雇员及董事。现有股份期权计划自采纳之日起10年内有效。根据现有股份期权 计划的计划规则，现有股份期权计划可由董事会于董事会会议上通过董事会决议案予以终止，无须经股 东批准。在此情况下，不得根据现有股份期权计划进一步授出股份期权。 ...

Core Viewpoint - The company has decided to terminate its existing share option plan effective December 8, 2025, and will propose a new share award plan at a special shareholders' meeting [1] Group 1: Share Option Plan - The existing share option plan was adopted on May 30, 2019, and is valid for 10 years from the date of adoption [1] - The board can terminate the existing share option plan through a resolution without needing shareholder approval [1] - No further share options can be granted under the existing plan following its termination [1] Group 2: New Share Award Plan - The board intends to propose a share award plan to shareholders, which will involve granting award shares [1] - The new share award plan requires shareholder approval at the special meeting to be implemented [1] - The plan aims to provide a competitive and attractive compensation package to incentivize selected participants to contribute to the company's growth and development [1]

格隆汇12月8日丨粤港湾控股(01396.HK)宣布，董事会拟于股东特别大会上向股东建议采纳股份奖励计 划。建议采纳股份奖励计划将涉及公司授出奖励股份。因此，采纳股份奖励计划将须待(其中包括)股东 于股东大会上批准后方可作实，并可为公司提供另一渠道，以具竞争力及吸引力的薪酬待遇激励选定参 与者为集团的增长及发展作出贡献，并使集团能够吸引及挽留最优秀的人才，以发展集团的业务。董事 (包括独立非执行董事)认为，采纳股份奖励计划符合市场惯例，激励合资格参与者致力提升企业价值及 实现长期目标，以谋求集团整体利益。 ...

（文章来源：证券日报） 证券日报网讯 12月8日，采纳股份在互动平台回答投资者提问时表示，截至2025年11月28日，公司登记 在册的公司股东数为8801户。 ...

证券日报网讯 12月4日晚间，采纳股份发布公告称，公司及全资子公司采纳医疗近日取得国家知识产权 局颁发的2项实用新型专利证书，专利名称分别为"一种通用型细菌过滤盒"（专利号 ZL202423196620.5，授权公告日2025年12月2日）和"一种注射器拧杆机构"（专利号 ZL202423192593.4，授权公告日2025年12月2日）。上述专利为公司自主研发，与公司主营业务技术相 关，虽不会短期显著影响业绩，但有助于完善知识产权保护体系、保持技术领先并提升核心竞争力。 （文章来源：证券日报） ...

| 序号 | 专利名称 | 专利类型 | 专利号 | 专利权人 | 授权公告日 | | --- | --- | --- | --- | --- | --- | | 1 | 一种通用型细菌过 | 实用新型 | ZL | 采纳股份 | 2025年12月2 | | | 滤盒 | | 202423196620.5 | | 日 | | 2 | 一种注射器拧杆机 | 实用新型 | ZL | 采纳医疗 | 2025年12月2 | | | 构 | | 202423192593.4 | | 日 | 上述专利为公司自主研发，其所涉及技术均与公司主营业务产品技术相关， 专利权自授权公告之日起生效。 上述专利的取得和运用，不会对公司短期的经营业绩构成重大影响，但有利 于公司进一步完善知识产权保护体系，形成持续创新机制，保持技术的领先地位， 提升公司的核心竞争力。 证券代码：301122 证券简称：采纳股份 公告编号：2025-094 采纳科技股份有限公司 关于公司及全资子公司取得专利证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 采纳科技股份有限公司（以下简称"公司"或" ...

Core Viewpoint - The company, Canan Co., Ltd., has experienced a significant decline in its financial performance, with a high price-to-earnings (PE) ratio compared to its industry peers, indicating potential overvaluation [1][2]. Company Summary - Canan Co., Ltd. closed at 27.7 yuan on December 3, with a 4.33% increase, resulting in a rolling PE ratio of 870.12, the lowest in 12 days, and a total market capitalization of 3.386 billion yuan [1]. - The company operates in the medical device sector, focusing on the research, production, and sales of injection and laboratory consumables, including safety injection needles and various types of syringes [1]. - As of the third quarter of 2025, the company reported a revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit of 8.25 million yuan, down 85.64%, with a gross profit margin of 24.45% [1]. Industry Summary - The average PE ratio for the medical device industry is 51.40, with a median of 39.68, positioning Canan Co., Ltd. at the 124th rank within the industry [1][2]. - The company is recognized as a specialized and innovative small and medium-sized enterprise in Jiangsu Province and is a provincial-level leading enterprise in agricultural industrialization [1].

Core Viewpoint - The stock of Canar Medical has seen a significant increase of 4.33% on December 3, with a trading volume of 144 million yuan and a market capitalization of 3.386 billion yuan [1] Group 1: Company Overview - Canar Medical, established on July 23, 2004, is located in Jiangyin, Jiangsu Province, and was listed on January 26, 2022 [7] - The company specializes in the research, production, and sales of medical and veterinary injection and puncture devices, as well as laboratory consumables [7] - The main revenue sources for the company are syringes (45.17%), puncture needles (45.01%), laboratory consumables (5.49%), and others (4.33%) [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported a revenue of 246 million yuan, representing a year-on-year decrease of 15.86% [7] - The net profit attributable to the parent company was 8.25 million yuan, showing a significant decline of 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Dynamics - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018, indicating a strategic partnership in the assisted reproductive technology sector [2] - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the Chinese yuan [3] - The stock has seen a net inflow of 15.7 million yuan from major investors today, marking a continuous increase in investment over the past three days [4][5]

Core Viewpoint - Jiufu Lai (08611) announced a proposal for a share scheme to comply with the revised GEM Listing Rules Chapter 23, effective from January 1, 2023, pending approval at a special shareholders' meeting [1] Group 1 - The board of Jiufu Lai has recommended the adoption of a share scheme [1] - The share scheme is subject to approval by shareholders at a special meeting [1]